Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

Expression of a splicing variant in the 5′-UTR of the human ERCC1 gene is not cancer related

Oncogene volume 24, pages 2110–2113 (2005)Cite this article

Abstract

Cisplatin is the most commonly used chemotherapeutic agent in the treatment of ovarian cancer. One of the mechanisms of resistance of ovarian tumours to cisplatin is increased nucleotide excision repair activity, in particular increased levels of the endonuclease ERCC1. Since 30–40% of ovarian cancers develop resistance to cisplatin after treatment and these tumours are usually incurable, ERCC1 expression is potentially useful as a predictive marker for the effectiveness of cisplatin-based chemotherapy. Using RT–PCR and Northern blotting, we have examined the expression of a 42 bp differentially spliced sequence in exon 1 of the human ERCC1 gene, loss of which has previously been reported to be correlated with higher levels of ERCC1 mRNA in ovarian cancer cell lines. We report here that this alternate transcript is ubiquitous in human tissues and cancer cell lines, is absent in mouse and thus does not appear to be cancer related.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  • Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ and Reed E . (1994). J. Clin. Invest., 94, 703–708.

  • Damia G, Imperatori L, Stefanini M and D'Incalci M . (1996). Int. J. Cancer, 66, 779–783.

  • Ferry KV, Hamilton TC and Johnson SW . (2000). Biochem. Pharmacol., 60, 1305–1313.

  • Hoy CA, Thompson LH, Mooney CL and Salazar EP . (1985). Cancer Res., 45, 1737–1743.

  • Isla D, Sarries C, Rosell R, Alonso G, Domine M, Taron M, Lopez-Vivanco G, Camps C, Botia M, Nunez L, Sanchez-Ronco M, Sanchez JJ, Lopez-Brea M, Barneto I, Paredes A, Medina B, Artal A and Lianes P . (2004). Ann. Oncol., 15, 1194–1203.

  • Johnson SW, Perez RP, Godwin AK, Yeung AT, Handel LM, Ozols RF and Hamilton TC . (1994). Biochem. Pharmacol., 47, 689–697.

  • Langdon SP, Lawrie SS, Hay FG, Hawkes MM, McDonald A, Hayward IP, Schol DJ, Hilgers J, Leonard RC and Smyth JF . (1988). Cancer Res., 48, 6166–6172.

  • Li Q, Tsang B, Bostick-Bruton F and Reed E . (1999). Biochem. Pharmacol., 57, 347–353.

  • Li T, Song Y, Liang X, Guo Y, Reed E and Yu JJ . (2004). Int. J. Oncol., 25, 1105–1111.

  • Masuda H, Ozols RF, Lai GM, Fojo A, Rothenberg M and Hamilton TC . (1988). Cancer Res., 48, 5713–5716.

  • Masuda H, Tanaka T, Matsuda H and Kusaba I . (1990). Cancer Res., 50, 1863–1866.

  • McGuire WP and Ozols RF . (1998). Semin. Oncol., 25, 340–348.

  • Parker RJ, Eastman A, Bostick-Bruton F and Reed E . (1991). J. Clin Invest., 87, 772–777.

  • Ryu JS, Hong YC, Han HS, Lee JE, Kim S, Park YM, Kim YC and Hwang TS . (2004). Lung Cancer, 44, 311–316.

  • Stoehlmacher J, Park DJ, Zhang W, Yang D, Groshen S, Zahedy S and Lenz HJ . (2004). Br. J. Cancer, 91, 344–354.

  • Thompson S, Clarke AR, Pow AM, Hooper ML and Melton DW . (1989). Cell, 56, 313–321.

  • Yu JJ, Thornton K, Guo Y, Kotz H and Reed E . (2001). Oncogene, 20, 7694–7698.

Download references

Acknowledgements

We thank Dr Grant Sellar (Cancer Research UK Centre, University of Edinburgh) for kindly providing the ovarian cancer cell lines and Dr Scott Bader (Sir Alastair Currie Cancer Research UK Laboratories, University of Edinburgh) for HPRT primers. This work was supported by a programme grant (C376/A1570) from Cancer Research UK to DWM.

Author information

Authors and Affiliations

  1. Sir Alastair Currie Cancer Research UK Laboratories, Molecular Medicine Centre, Western General Hospital, University of Edinburgh, Edinburgh, EH4 2XU, UK

    Andrew G Winter, Clare Dorgan & David W Melton

Authors
  1. Andrew G Winter
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Clare Dorgan
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David W Melton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to David W Melton.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Winter, A., Dorgan, C. & Melton, D. Expression of a splicing variant in the 5′-UTR of the human ERCC1 gene is not cancer related. Oncogene 24, 2110–2113 (2005). https://doi.org/10.1038/sj.onc.1208400

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1208400

Keywords

This article is cited by

Search

Advanced search

Quick links